CSL (ASX:CSL) has reported a net profit after tax of $2.01 billion for the six months to the ned of December 2024, up 7 per cent on a constant currency basis.
CEO and managing director Dr Paul McKenzie said, "CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig [immunoglobulin] franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans.
"CSL Seqirus was negatively impacted by significantly low influenza immunisation rates, particularly in the United States. "
CSL Vifor grew sales, underpinned by robust iron volumes in Europe and the expansion of our nephrology products."
CSL Behring reported immunoglobulin sales of $3.174 billion, up 15 per cent. Albumin sales rose 9 per cent to $672 million, while haemophilia product sales increased 11 per cent to $731 million.
The company said plasma collections continue to grow with the cost of collections decreasing.
CSL Seqirus reported a 9 per cent decline in revenue to $1.661 billion. The company attributed the decline to low immunisation rates, particularly in the US, impacting the broader influenza vaccine market.
CSL Vifor reported a 6 per cent increase in revenue to $1.079 billion.
Commenting on CSL's outlook, Dr McKenzie said, "The fundamentals of CSL's underlying business units are robust, and we are in a strong position to deliver annualised double-digit earnings growth over the medium term."
Dr McKenzie said the company anticipates full-year revenue growth of 5 to 7 per cent at constant currency. It expects profit in the range of $3.2 billion to $3.3 billion at constant currency, representing growth of 10 to 13 per cent.
"Our therapies continue to be valued by patients and healthcare systems around the world, as demonstrated by the continued growth of our core Ig franchise and the solid uptake of new product launches by CSL Vifor," he said.
"In CSL Behring we will continue to focus on improving our gross margins, which will be aided by the expected completion of the RIKA roll-out across CSL Plasma by the end of the financial year.
"While the market conditions for CSL Seqirus remain challenging, influenza will continue to be a burden to public health systems. We believe our differentiated strategy is well placed to grow market share.
"For CSL Vifor, the iron market growth remains strong and we expect to maintain a leadership position. We will also build on the momentum in our nephrology business."
